Ribosomal immunotherapy for recurrent respiratory tract infections in children.
Recurrent respiratory tract infections are common in children. They reflect the immaturity of the immune system in its encounter with environmental antigens. Little or no specific protective immune response has yet been established. These infections represent an important public health problem in terms of both treatment (anti-inflammatory or antibacterial drugs for children) and economy. Immunotherapy has been proposed as a means of preventing these recurrent infections by providing children with small doses of inactive bacterial antigens liable to trigger specific and protective immune responses. Among such drugs, ribosomal preparations (to which this review is limited) appear to be not only well tolerated, but also ideally targeted to induce mucosal responses. One preparation of ribosomal mucosal vaccine is commercially available in several countries. Numerous clinical trials in the world have confirmed the positive role of this mucosal ribosomal bacterial vaccine in significantly reducing the number of infections, courses of antibacterials, and absenteeism. In vitro and ex vivo investigations have confirmed that such vaccines indeed trigger protective specific immune responses.
Béné
Marie C
MC
Immunology Laboratory of the University Hospital, Faculty of Medicine of Nancy, Nancy, France. bene@grip.u-nancy.fr
Faure
Gilbert C
GC
D001428:Bacterial Vaccines; D002648:Child; D002986:Clinical Trials as Topic; D017850:Economics, Pharmaceutical; D006801:Humans; D018928:Immunity, Mucosal / Q000502:physiology; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D012270:Ribosomes / Q000276:immunology*; D014611:Vaccination
D001428:Bacterial Vaccines